{"id":"W4404406138","doi":"10.1016/j.ejca.2024.115122","title":"A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Oncology; Phase (matter); Internal medicine; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001121607,0.001526035,0.002233858,0.0004184609,0.0005186635,0.001091516,0.0006744501,0.00105026,0.004018018],"category_scores_gemma":[0.0005783557,0.0006413761,0.001410903,0.0003941497,0.00071633,0.0007767999,0.0003581219,0.003537541,0.0008522142],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001035626,"about_ca_system_score_gemma":0.001374297,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001629846,"about_ca_topic_score_gemma":0.004490132,"domain_scores_codex":[0.9997085,0.0001018365,0.000009731933,0.00004755214,0.00002117983,0.0001111221],"domain_scores_gemma":[0.999554,0.00005897603,0.00004892499,0.00004399331,0.00002326599,0.0002707708],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6490821,0.1008544,0.007381164,0.0009092399,0.001820861,0.0004139667,0.0004640919,0.006396338,0.07452692,0.0004643447,0.009903743,0.147783],"study_design_scores_gemma":[0.5306763,0.4380343,0.01493516,0.00003591687,0.0005682273,0.0004184291,0.0001121052,0.001775391,0.006715682,0.0003995375,0.006280781,0.0000482076],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922694,0.001936213,0.0006667628,0.0005392506,0.000122702,0.001516735,0.001467313,0.0001243125,0.001357293],"genre_scores_gemma":[0.9850681,0.002118935,0.002009756,0.001092515,0.0001223148,0.002020604,0.003269938,0.00007368284,0.004224032],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004018018,"threshold_uncertainty_score":0.01344156,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007978048884716541,"score_gpt":0.2706501542859294,"score_spread":0.2626721054012128,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}